Transgender women with HIV were more likely to have subclinical hypothyroidism and adrenal insufficiency than cisgender men with HIV.
Transgender women (people assigned male at birth who identify as female) are at high risk for HIV infection (estimated worldwide prevalence, at least 19%). Data are limited regarding the frequency of endocrine and metabolic abnormalities in transgender women with HIV and the impact of gender-affirming hormones on antiretroviral drugs (ARVs) and HIV treatment outcomes. To address these questions, investigators conducted a matched case-control study comparing 100 transgender women with HIV to 197 cisgender men with HIV.
Almost all participants (97%) were on ARVs; about half were on an HIV protease inhibitor. Thirty-one percent of transgender women reported current hormone intake (mostly estrogens), and 60% reported previous hormone use. Cortic…
Reviewing Authors
Robert Goldstein, MD, PhD
Robert Goldstein, MD, PhD
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)